December 21, 2018

Novocure to Participate in the 37th Annual J.P. Morgan Healthcare Conference

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) will participate in the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 9, 2019, in San Francisco. William Doyle, Novocure’s Executive Chairman, will speak on behalf of the company and address questions from analysts. He is scheduled to present at 2:30… Read More
learn more
December 21, 2018

Novocure to Participate in the 37th Annual J.P. Morgan Healthcare Conference

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) will participate in the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 9, 2019, in San Francisco. William Doyle, Novocure’s Executive Chairman, will speak on behalf of the company and address questions from analysts. He is scheduled to present at 2:30… Read More
learn more
December 17, 2018

Novocure and the AACR Announce Four Inaugural Research Grants to Promote and Support Innovative Research on Tumor Treating Fields

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) and the American Association for Cancer Research (AACR) announce four inaugural Tumor Treating Fields research grants. The grants represent a joint effort to promote and support innovative research on Tumor Treating Fields. Tumor Treating Fields is a cancer therapy that uses electric… Read More
learn more
December 17, 2018

Novocure and the AACR Announce Four Inaugural Research Grants to Promote and Support Innovative Research on Tumor Treating Fields

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) and the American Association for Cancer Research (AACR) announce four inaugural Tumor Treating Fields research grants. The grants represent a joint effort to promote and support innovative research on Tumor Treating Fields. Tumor Treating Fields is a cancer therapy that uses electric… Read More
learn more
December 6, 2018

Sub-Group Analysis of Novocure’s EF-14 Phase 3 Pivotal Trial in Newly Diagnosed Glioblastoma Published in Journal of Neuro-Oncology Demonstrating More Time on Optune® Predicted Increased Survival

Patients who used Optune more than 90 percent of the time experienced a median overall survival of 24.9 months Monthly usage was a predictor of survival, independent of other prognostic factors such as Karnofsky Performance Score, age, or MGMT methylation status ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR)… Read More
learn more
December 6, 2018

Sub-Group Analysis of Novocure’s EF-14 Phase 3 Pivotal Trial in Newly Diagnosed Glioblastoma Published in Journal of Neuro-Oncology Demonstrating More Time on Optune® Predicted Increased Survival

Patients who used Optune more than 90 percent of the time experienced a median overall survival of 24.9 months Monthly usage was a predictor of survival, independent of other prognostic factors such as Karnofsky Performance Score, age, or MGMT methylation status ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR)… Read More
learn more
November 14, 2018

Novocure and Zai Lab Awarded Deal of the Year at 5th Annual BioCentury China Healthcare Summit in Shanghai, China

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that Novocure and Zai Lab have received the Deal of the Year Award from BayHelix at a ceremony during the 5th annual BioCentury China Healthcare Summit in Shanghai, China. The award is part of the BayHelix China Healthcare Awards series, celebrating… Read More
learn more
November 14, 2018

Novocure and Zai Lab Awarded Deal of the Year at 5th Annual BioCentury China Healthcare Summit in Shanghai, China

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that Novocure and Zai Lab have received the Deal of the Year Award from BayHelix at a ceremony during the 5th annual BioCentury China Healthcare Summit in Shanghai, China. The award is part of the BayHelix China Healthcare Awards series, celebrating… Read More
learn more
November 13, 2018

Novocure Announces More than 70 Presentations on Tumor Treating Fields at 23rd Annual Meeting of the Society for Neuro-Oncology

Presentations span 21 research areas with five oral presentations More than 50 presentations from external authors indicate a growing interest Novocure’s proprietary Tumor Treating Fields platform ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today announced more than 70 presentations on Tumor Treating Fields, including five oral presentations,… Read More
learn more
November 13, 2018

Novocure Announces More than 70 Presentations on Tumor Treating Fields at 23rd Annual Meeting of the Society for Neuro-Oncology

Presentations span 21 research areas with five oral presentations More than 50 presentations from external authors indicate a growing interest Novocure’s proprietary Tumor Treating Fields platform ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today announced more than 70 presentations on Tumor Treating Fields, including five oral presentations,… Read More
learn more